BRPI0806902A2 - MÉTODOS E COMPOSIÇÕES PARA MODULAÇÃO DAS VIAS DE METILAÇÃO DE DNA DIRECIONADA POR sIRNA E RNA - Google Patents

MÉTODOS E COMPOSIÇÕES PARA MODULAÇÃO DAS VIAS DE METILAÇÃO DE DNA DIRECIONADA POR sIRNA E RNA

Info

Publication number
BRPI0806902A2
BRPI0806902A2 BRPI0806902-6A2A BRPI0806902A BRPI0806902A2 BR PI0806902 A2 BRPI0806902 A2 BR PI0806902A2 BR PI0806902 A BRPI0806902 A BR PI0806902A BR PI0806902 A2 BRPI0806902 A2 BR PI0806902A2
Authority
BR
Brazil
Prior art keywords
methods
sirna
rna
compositions
modulation
Prior art date
Application number
BRPI0806902-6A2A
Other languages
English (en)
Inventor
Lionel Navarro
Olivier Voinnet
Original Assignee
Plant Bioscience Ltd
Lionel Navarro
Olivier Voinnet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plant Bioscience Ltd, Lionel Navarro, Olivier Voinnet filed Critical Plant Bioscience Ltd
Publication of BRPI0806902A2 publication Critical patent/BRPI0806902A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8281—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for bacterial resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
BRPI0806902-6A2A 2007-01-19 2008-01-18 MÉTODOS E COMPOSIÇÕES PARA MODULAÇÃO DAS VIAS DE METILAÇÃO DE DNA DIRECIONADA POR sIRNA E RNA BRPI0806902A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88141807P 2007-01-19 2007-01-19
PCT/IB2008/000954 WO2008087561A2 (en) 2007-01-19 2008-01-18 Methods and compositions for modulating the sirna and rna-directed-dna methylation pathways

Publications (1)

Publication Number Publication Date
BRPI0806902A2 true BRPI0806902A2 (pt) 2014-06-17

Family

ID=39636444

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0806902-6A2A BRPI0806902A2 (pt) 2007-01-19 2008-01-18 MÉTODOS E COMPOSIÇÕES PARA MODULAÇÃO DAS VIAS DE METILAÇÃO DE DNA DIRECIONADA POR sIRNA E RNA

Country Status (6)

Country Link
US (1) US20100169996A1 (pt)
EP (1) EP2121939B1 (pt)
BR (1) BRPI0806902A2 (pt)
CA (1) CA2675946A1 (pt)
ES (1) ES2447840T3 (pt)
WO (1) WO2008087561A2 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103301475B (zh) 2005-12-28 2016-08-03 斯克里普斯研究所 药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用
WO2008080017A1 (en) * 2006-12-21 2008-07-03 Novozymes, Inc. Methods of reducing or eliminating expression of genes in filamentous fungal strains by transitive rna interference
MY188457A (en) 2008-10-03 2021-12-10 Opko Curna Llc Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
WO2010065671A2 (en) 2008-12-04 2010-06-10 Curna, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
CA2745329C (en) 2008-12-04 2022-07-12 Opko Curna, Llc Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
KR20110091796A (ko) 2008-12-04 2011-08-12 오피케이오 큐알엔에이, 엘엘씨 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
HUE026280T2 (en) 2009-02-12 2016-06-28 Curna Inc Treatment of brain-derived neurotrophic factor (BDNF) -related diseases by inhibition of natural antisense transcripts associated with BDNF \ t
MX2011009751A (es) 2009-03-16 2011-09-29 Opko Curna Llc Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2.
US9708604B2 (en) 2009-03-17 2017-07-18 Curna, Inc. Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1
ES2609655T3 (es) 2009-05-06 2017-04-21 Curna, Inc. Tratamiento de enfermedades relacionadas con tristetraprolina (TTP) mediante inhibición de transcrito antisentido natural para TTP
CN102459596B (zh) 2009-05-06 2016-09-07 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
EP2427554B1 (en) 2009-05-08 2016-11-16 CuRNA, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
DK2432881T3 (en) 2009-05-18 2018-02-26 Curna Inc TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
KR101703695B1 (ko) 2009-05-22 2017-02-08 큐알엔에이, 인크. 전사 인자 ｅ3(ｔｆｅ3)에 대한 천연 안티센스 전사체의 억제에 의해 ｔｆｅ3 및 인슐린 수용체 기질 2(ｉｒｓ2)의 치료
KR101704988B1 (ko) 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
WO2010148050A2 (en) 2009-06-16 2010-12-23 Curna, Inc. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
ES2629339T3 (es) 2009-06-16 2017-08-08 Curna, Inc. Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
ES2618894T3 (es) 2009-06-24 2017-06-22 Curna, Inc. Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
CN102482672B (zh) 2009-06-26 2016-11-09 库尔纳公司 通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
KR101801407B1 (ko) 2009-07-24 2017-11-24 큐알엔에이, 인크. 시르투인 (ｓｉｒｔ)에 대한 천연 안티센스 전사체의 억제에 의한 시르투인 관련된 질환의 치료
CA2769665A1 (en) 2009-08-05 2011-02-10 Opko Curna, Llc Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
US9044493B2 (en) 2009-08-11 2015-06-02 Curna, Inc. Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin
CN102482670B (zh) 2009-08-21 2018-06-15 库尔纳公司 通过抑制‘hsp70-相互作用蛋白的c末端’(chip)的天然反义转录物而治疗chip相关疾病
CN102482671B (zh) 2009-08-25 2017-12-01 库尔纳公司 通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病
NO2480669T3 (pt) 2009-09-25 2018-04-07
CA2782366A1 (en) 2009-12-16 2011-07-14 Opko Curna, Llc Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
US8940708B2 (en) 2009-12-23 2015-01-27 Curna, Inc. Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
EP2515947B1 (en) 2009-12-23 2021-10-06 CuRNA, Inc. Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
US8921334B2 (en) 2009-12-29 2014-12-30 Curna, Inc. Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
ES2585829T3 (es) 2009-12-29 2016-10-10 Curna, Inc. Tratamiento de las enfermedades relacionadas con la proteína tumoral 63 (p63) por inhibición de transcripción antisentido natural a p63
CA2785727C (en) 2009-12-31 2020-01-07 Curna, Inc. Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
US8946181B2 (en) 2010-01-04 2015-02-03 Curna, Inc. Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
RU2612161C2 (ru) 2010-01-06 2017-03-02 Курна, Инк. Лечение заболеваний, связанных с геном развития поджелудочной железы, путем ингибирования природного антисмыслового транскрипта к гену развития поджелудочной железы
NO2524039T3 (pt) 2010-01-11 2018-04-28
ES2671877T3 (es) 2010-01-25 2018-06-11 Curna, Inc. Tratamiento de enfermedades relacionadas con la RNASA (H1) mediante inhibición del transcrito antisentido natural a RNASA H1
WO2011103528A2 (en) 2010-02-22 2011-08-25 Opko Curna Llc Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
CN102869777B (zh) 2010-04-02 2018-11-02 库尔纳公司 通过抑制集落刺激因子3(csf3)的天然反义转录物而治疗csf3相关疾病
WO2011127337A2 (en) 2010-04-09 2011-10-13 Opko Curna Llc Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
RU2693462C2 (ru) 2010-05-03 2019-07-03 Курна, Инк. Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
TWI586356B (zh) 2010-05-14 2017-06-11 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
WO2011150005A2 (en) 2010-05-26 2011-12-01 Opko Curna Llc Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
DK2576784T3 (en) 2010-05-26 2018-02-26 Curna Inc TREATMENT OF METHIONIN SULPHOXIDE REDUCTASE A (MSRA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MSRA
CN109112126B (zh) 2010-06-23 2024-06-14 库尔纳公司 通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
CN103068982B (zh) 2010-07-14 2017-06-09 库尔纳公司 通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病
US8993533B2 (en) 2010-10-06 2015-03-31 Curna, Inc. Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
CN103180445B (zh) 2010-10-22 2018-02-16 库尔纳公司 通过抑制α‑L‑艾杜糖醛酸酶(IDUA)的天然反义转录物而治疗IDUA相关疾病
EP2640738A1 (en) * 2010-11-15 2013-09-25 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Anti-fungal agents
WO2012068340A2 (en) 2010-11-18 2012-05-24 Opko Curna Llc Antagonat compositions and methods of use
US8987225B2 (en) 2010-11-23 2015-03-24 Curna, Inc. Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG
WO2012170771A1 (en) 2011-06-09 2012-12-13 Curna, Inc. Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
KR101991980B1 (ko) 2011-09-06 2019-06-21 큐알엔에이, 인크. 소형 분자로 전압-개폐된 나트륨 채널 (SCNxA)의 알파 아단위에 관련된 질환의 치료
ES2694592T3 (es) 2012-03-15 2018-12-21 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado del cerebro (BDNF) por inhibición del transcrito antisentido natural de BDNF
WO2014028833A1 (en) * 2012-08-17 2014-02-20 Novozymes A/S Methods for co-silencing expression of genes in filamentous fungal strains and uses thereof
CN109554496A (zh) * 2018-12-17 2019-04-02 北京林业大学 一种检测胁迫处理前后植物中转座子活性变化的方法
CA3209014A1 (en) * 2021-02-19 2022-08-25 Nuclear Rna Networks, Inc. Compositions and methods for modulating gene transcription networks based on shared high identity transposable element remnant sequences and nonprocessive promoter and promoter-proximal transcript
US20250270583A1 (en) * 2022-10-26 2025-08-28 Biodrive, Inc. Methods for Suppression of Gene Silencing in Plants
CN116622739B (zh) * 2023-06-25 2023-11-28 中国农业科学院植物保护研究所 番茄SlSUVH2或SlSUVH4基因在调控双生病毒中的应用及转基因植物培育方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4031758A1 (de) 1990-10-06 1992-04-09 Bayer Ag Resistenz-gene
US5629470A (en) * 1995-01-20 1997-05-13 Rutgers, The State University Of New Jersey Transgenic plants and plant cells with enhanced pathogen resistance and related methods
GB0021879D0 (en) 2000-09-06 2000-10-18 Univ Edinburgh Plant resistance gene

Also Published As

Publication number Publication date
WO2008087561A9 (en) 2009-10-15
WO2008087561A8 (en) 2008-10-09
EP2121939A2 (en) 2009-11-25
EP2121939B1 (en) 2013-12-04
WO2008087561A3 (en) 2009-04-09
WO2008087561A2 (en) 2008-07-24
US20100169996A1 (en) 2010-07-01
ES2447840T3 (es) 2014-03-13
CA2675946A1 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
FR2929502B1 (fr) Implant nucleique.
DK2417257T3 (da) Tricyclo-dna-antisense-oligonukleotider, sammensætninger, og fremgangsmåder til behandlingen af sygdom
BRPI0815725A2 (pt) Métodos para detecção de oligonucleotídeos
DK2200646T3 (da) RNA-Vacciner
GB201014134D0 (en) Methods of RNA aplification in the presence of DNA
BRPI0812446A2 (pt) Métodos para aperfeiçoamento de propriedades de proteína múltiplas
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0716439A2 (pt) formulaÇÕes de flibanserina e mÉtodo para fabricaÇço das mesmas.
BRPI0922122A2 (pt) composições e métodos para tratamento de doença celíaca.
BRPI0912046A2 (pt) composições de hibridização e métodos
BRPI0811170A2 (pt) Oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila
BRPI0908876A2 (pt) barreiras para facilitação de reações biológicas
BRPI0919252A2 (pt) Métodos para cultivar células, propagação e purificação de vírus
BRPI0718796A2 (pt) Nucleotídeo
BRPI0909212A2 (pt) Composições e método para sequeciamento de ácido nucléico
BRPI0815841A2 (pt) Métodos e composições para melhoramento de traços preferidos.
EP2131749A4 (en) Surgical stapling apparatus
PT2231689T (pt) Novos nucleósidos 7-deazapurina citostáticos
BRPI0809573A8 (pt) composição, e, método
DK1984502T3 (da) Nukleinsyre
EP2263082A4 (en) ANALYSIS OF BLOOD VISCOSITY
DE112009000578A5 (de) Reibahle
BRPI0921959A2 (pt) métodos e composições para remoção de tatuagem
DE502007005526D1 (de) Pipettiervorrichtung
EP2131746A4 (en) HIGH DRIVING FOR MEDICAL APPLICATIONS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.